文献速递神经肿瘤

肿瘤相关巨噬细胞来源外泌体通过靶向m6A修饰的FOXD1调控SHH型髓母细胞瘤的免疫治疗敏感性

Tumor-associated macrophage-derived exosomes modulate the immunotherapeutic sensitivity of SHH-medulloblastoma by targeting m6A-modified FOXD1.
PubMed 文献 · Neuro Oncol · 2025-01-01

本研究在40例SHH型髓母细胞瘤(SHH-MB)中评估m6A修饰相关蛋白表达,用甲基化RNA免疫沉淀测序鉴定TAM来源外泌体影响的基因,并在NeuroD2:SmoA1小鼠模型中研究FOXD1的m6A修饰机制及AAV2/9-shFOXD1联合PD-1抑制剂治疗。结果显示TAM来源外泌体降低METTL14表达和m6A水平,FOXD1为关键下游靶点,敲低FOXD1促进CXCL10/11释放和CD8+ T细胞募集,并增强PD-1抑制剂抗肿瘤效果。

要点

  • TAM来源外泌体经METTL14特异性microRNA降低METTL14表达和m6A修饰水平。
  • FOXD1是TAM来源外泌体的关键下游靶点,其表达与SHH-MB不良预后相关。
  • 敲低FOXD1促进CXCL10/11释放和CD8+ T细胞募集,增强PD-1抑制剂抗肿瘤效果。

核心结论

  • TAM来源外泌体调控SHH-MB的m6A水平,经FOXD1促进肿瘤进展;FOXD1是使SHH-MB对免疫检查点阻断敏感的新治疗靶点。

研究设计与样本

  • 在40例SHH-MB中评估m6A修饰相关蛋白表达,用甲基化RNA免疫沉淀测序鉴定TAM来源外泌体影响的基因。
  • 在NeuroD2:SmoA1小鼠模型中评估FOXD1的m6A修饰机制及AAV2/9-shFOXD1联合PD-1抑制剂的治疗。

主要发现

  • TAM浸润导致METTL14表达降低,由含METTL14特异性microRNA的TAM来源外泌体介导,进而使m6A修饰水平降低。
  • FOXD1被鉴定为TAM来源外泌体的关键下游靶点,其表达水平与SHH-MB不良预后相关。
  • 敲低SHH-MB细胞中的FOXD1显著促进趋化因子CXCL10/11释放,导致CD8+ T细胞募集。
  • 在转基因SHH-MB小鼠中,AAV2/9-shFOXD1治疗显著增强PD-1抑制剂的抗肿瘤效果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medulloblastoma (MB) is the most common pediatric malignant brain tumor. Infiltration of tumor-associated macrophages (TAMs) and m6A modification of RNA are correlated with poor prognosis and tumor progression in the Sonic Hedgehog (SHH) subtype (SHH-MB). However, the relationship between TAMs infiltration in SHH-MB and m6A modification status during tumor progression remains unclear. METHODS: Expression of m6A modification-related proteins was assessed in 40 cases of SHH-MB. Genes affected by TAM-derived exosomes were identified with methylated RNA immunoprecipitation sequencing. Mechanisms of m6A modification of FOXD1 were evaluated and combinatorial treatment with AAV2/9-shFOXD1 and PD-1 inhibitors was investigated in the NeuroD2:SmoA1 mouse model. RESULTS: TAMs infiltration led to decreased METTL14 expression, which was mediated by TAM-derived exosomes containing METTL14-specific microRNAs. In turn, this led to lower levels of m6A modifications. Through a screen, FOXD1 was identified as a critical downstream target of TAM-derived exosomes, and its expression level was correlated with poor prognosis in SHH-MBs. Importantly, knockdown of FOXD1 in SHH-MB cells significantly promoted the release of chemokines CXCL10/11, resulting in CD8+ T cell recruitment. Furthermore, treatment with AAV2/9-shFOXD1 significantly enhanced the antitumor effect of the PD-1 inhibitor in transgenic SHH-MB mice. CONCLUSIONS: Our study revealed for the first time that TAM-derived exosomes modulate m6A levels in SHH-MB, which promotes tumor progression via FOXD1. We identified FOXD1 as a novel therapeutic target whose inhibition sensitizes SHH-MB to immune checkpoint blockade.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Liu Y, Peng Y, Song C, et al. Tumor-associated macrophage-derived exosomes modulate the immunotherapeutic sensitivity of SHH-medulloblastoma by targeting m6A-modified FOXD1. Neuro Oncol. 2025. PMID: 40401803. doi:10.1093/neuonc/noaf123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。